Evidence map›Paper›PMID 39671088›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms.

Christina Kanaan, Mohamed-Amine Bani, Michel Ducreux, David Planchard, Livia Lamartina, Sophie Moog, Thomas Pudlarz, Eric Baudin, Julien Hadoux, Abir Al-Ghuzlan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Associations ofFrontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christina KanaanDepartment of Pathology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif cedex, France.
Mohamed-Amine BaniDepartment of Pathology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif cedex, France.
Michel DucreuxDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
David PlanchardDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
Livia LamartinaDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.
Sophie MoogDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.
Thomas PudlarzDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
Eric BaudinDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.
Julien HadouxDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.
Abir Al-GhuzlanDepartment of Pathology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif cedex, France.
Jean-Yves ScoazecDepartment of Pathology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif cedex, France. jy.scoazec@gmail.com.ORCID http://orcid.org/0000-0003-1604-6823

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The double inactivation of TP53 and RB1 is considered typical of neuroendocrine carcinomas (NECs) but is assumed to be rare in high-grade neuroendocrine tumors (NETs). The immunohistochemical determination of the p53 and Rb status has therefore been proposed as a diagnostic tool. We studied this status in a large series of high-grade neuroendocrine neoplasms, from multiple origins, in order to (a) assess the patterns observed in the different histopathological categories, (b) compare them between the various anatomic sites, and (c) evaluate their possible diagnostic relevance. Four hundred sixty-five cases from 9 organ systems (142 high-grade NETs -NET-G3-, 162 large-cell NECs -LCNEC-, 144 small-cell NECs -SCNEC-) and 60 cases of NET G1/G2 were included. The expression of both proteins was normal in 96.7% of NET G1/G2, 76.7% of NET-G3, and 5.8% of all NECs. p53 expression was abnormal in 12.7% of NET-G3 and 91.5% of NECs. Rb expression was lost in 10.6% of NET-G3 and 68.3% of NECs. Rb loss was significantly less frequent in LCNEC than in SCNEC (57.3% versus 80.6%); abnormal p53 expression was comparable in the two categories. Patterns were comparable between primary sites, except for head and neck NECs. For diagnostic purposes, taking into account, Rb status improved, but only marginally, the performances of p53 status. In conclusion, our study underlines the molecular heterogeneity of NET-G3 and LCNEC, irrespectively of the primary, and provides further insight on the diagnostic relevance of p53/Rb immunodetection in high-grade neuroendocrine neoplasms.

Indexed as

Biomarkers, TumorNeuroendocrine TumorsRetinoblastoma Binding ProteinsTumor Suppressor Protein p53AdolescentAdultAgedAged, 80 and overCarcinoma, NeuroendocrineFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm GradingUbiquitin-Protein LigasesBiomarkers, TumorRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesImmunohistochemistryNeuroendocrine neoplasmsP53Rb

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.